August 27, 2008 - Cordis Corp. today said it received CE mark approval to market the CYPHER SELECT Plus Sirolimus-eluting coronary stent for the treatment of acute myocardial infarction (AMI).
CE mark approval means the product has been deemed safe and effective for treatment of AMI and can now be promoted for this indication in all member states of the European Union (EU), European Economic Area and Switzerland.